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Introduction. Chronic lymphocytic leukaemia (CLL) is an incurable disease of the elderly, characterised by gradual accu-
mulation of small mature B lymphocytes which escape apoptosis through inflammatory signals from the microenviron-
ment. Elevated inflammatory markers are associated with very poor prognosis in different types of cancer. Therefore, we 
examined retrospectively the impact of platelet lymphocyte ratio (PLR) and platelet distribution width (PDW) on 180 CLL 
patients’ outcome.
Materials and methods. This retrospective study included 180 patients with CLL who were diagnosed and selected 
among cases referred to the Oncology Center Mansoura University between January 1st, 2008 and June 30th, 2016. All the 
relevant information was collected from the electronic medical records of the selected patients. 
Results. Our results revealed that low PLR (<2.5) was more frequently observed in patients with stage C (p < 0.001), with 17p 
deletion (p = 0.017), and CD38 expression (p = 0.08), but not with seropositive HCV patients (p = 0.2). High PDW (≥18.5 fl) 
was more frequently associated with intention to treat population (p = 0.038), and CD38 expression (p = 0.068), but not 
with 17p deletion (p = 0.25) and seropositive HCV patients (p = 0.4). Multivariate analysis for overall survival showed that 
stage A and low PDW were independent factors for overall survival (p = 0.014 and 0.04 respectively), while high PLR (p = 
0.05), and seronegative HCV patients (p = 0.1) lost their significance. 
Conclusion. Our data showed that low PLR and high PDW were associated with poor prognostic markers. Stage C-CLL 
and high PDW were independent predictors of survival.  
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Introduction 
Chronic lymphocytic leukaemia (CLL) is an incurable di sease 
that is characterized by gradual accumulation of small mature 
B lymphocytes [1]. These lymphocytes are dormant replica-
tional cells that accumulate in the marrow and peripheral 
blood, due to extrinsic survival signals from the microenvi-
ronment [2]. 
These leukaemic lymphocytes can resist apoptosis by in-
flammatory signals compared to normal B lymphocytes. Actual-
ly, CLL patients present with manifestations that typically occur 
in chronic inflammatory disorders which make the role of inflam-
mation clear [3]. Thrombocytopenia in CLL patients caused by 
either bone marrow infiltration, immune thrombocytopenia, 
hypersplenism, or myelosuppression secondary to cytotoxic 
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therapy or infection [4]. PLR is a novel inflammatory marker that 
can be applied in many diseases for predicting inflammation, 
and PDW represents the platelet anisocytosis and is calculated 
from the distribution of individual platelet volumes [5].
Further, platelet-to-lymphocyte ratio (PLR) finds its role in CLL 
that the lymphocyte and platelet counts are correlated to the 
pathogenesis of CLL directly and affect management of patients. 
Also, PDW does not assess heterogeneity of platelet volume only, 
but also platelet activity [6]. Many studies have shown that these 
two inflammatory biomarkers (PLR and PDW) are considered 
prognostic factors for some non-haematological tumours [5].
To our knowledge, PDW has not been studied in CLL. So, 
in our study, we aimed at investigating the role of PLR and 
PDW in our CLL patients.
Materials and methods 
Subjects
This retrospective study included 180 patients with CLL who 
were diagnosed and selected among cases referred to the 
Oncology Center Mansoura University (OCMU) between Janu-
ary 1th, 2008 and June 30th, 2016. All the relevant information 
was obtained through the electronic medical records of the 
selected patients. All laboratory procedures were performed in 
the clinical pathology labs of OCMU. The Binet staging system 
was used to classify the CLL patients: 
• Binet stage A: <3 areas of lymphoid tissue are enlarged, 
with no anaemia or thrombocytopenia.
• Binet stage B:  ≥3 areas of lymphoid tissue are enlarged, 
with no anaemia or thrombocytopenia.
• Binet stage C: anaemia (<10 g/dL) and/or thrombocytope-
nia (<100 × 109/L) are present. Any number of lymphoid 
tissue areas may be enlarged.
They were treated according to our institute guidelines 
based on performance statue by purine based regimen or 
alkylators. As far as we know, patients with immune-related 
cytopenia or infection were excluded from our study. 
Patient evaluation
Detailed history taking and clinical examination. Laboratory 
investigations:
1. Routine work: 
• Complete blood count (haemogram): using the electronic 
counter (CELL-DYN 3700, Abbott, Canada), PDW and PLR 
were obtained, before any treatment, including PDW (fl), the 
lymphocyte count (k/uL) and platelet count (k/uL). We cal-
culated the PLR by dividing the absolute count of platelets 
to that of lymphocytes at diagnosis with thorough examina-
tion of peripheral blood smears stained with Leishman stain. 
• Liver function tests, serum creatinine, serum uric acid, 
and serum LDH. 
• Virology screen (HCV, HBsAg, HIV): HCV Ab was detected 
using Murex HCV Ag/Ab Combination 4th generation ELISA 
kit # 4J2453 Anti-Core monoclonal antibody, recombinant 
antigen and peptides representing the immunodominant 
regions of NS3 and core. Simultaneously, the Bioelisa ELISA 
kit was used for detection of Hepatitis B surface antigen 
(HBsAg). Genscreen™ ULTRA HIV Ag-Ab. The Genscreen™ 
ULTRA HIV Ag-Ab is a qualitative enzyme immunoassay 
kit for the detection of HIV p24 antigen and antibodies to 
HIV-1 (groups M and O) and HIV-2 in human serum or 
plasma. 
2. Work up for CLL diagnosis: 
• Microscopic study of bone marrow and peripheral smears. 
• Immunophenotyping (IPT) using American (BD FACSCAN-
TOII) to diagnose the cases and exclude other types of 
lymphoma by incubation of washed cells from peripheral 
blood or bone marrow samples with fluorescein-labelled 
monoclonal antibody including scoring system of CLL 
(CD5, CD19,CD23,CD79b,sIgM,CD38), kappa and lambda. 
Positivity in each marker can be calculated if it is more 
than 20%. 
• FISH for detection of 17p deletion. Interphase FISH tech-
nique was conducted on peripheral blood or bone mar-
row aspiration and trephine. Using the Olympus BX 61, 
fluorescent microscope. Interphase FISH technique was 
performed on samples after optimization of the protocol 
using commercially available probe from Cytocell UK LPH 
TP53 deletion FISH Probe Kit.
Statistical analysis
Data were analysed on a personal computer running SPSS© 
for Windows (Statistical Package for Social Scientists) Release 
18. A two-tailed p value of >0.05 was considered statistically 
significant. For descriptive statistics of qualitative variables, the 
frequency distribution procedure was run with calculation of 
the number of cases and percentages. For descriptive statistics 
of quantitative variables, the median and range were used. 
Association between categorical variables was tested by the 
Chi Square Test or Fishers exact test. The independent- samples 
t-test was used to compare the means between two groups. 
Time to treat was defined as the time from diagnosis until the 
start of chemotherapy or death. Overall survival was calculated 
by the Kaplan-Meier Product-Limit Estimator. Comparison of 
the survival was performed by the Log-Rank Test. Exploring 
variables for their independent prognostic effect on survival 
was carried out using the multivariate stepwise Cox’s propor-
tional regression hazard model. 
Results 
The 180 CLL patients were (101 M; 79 F) with mean age 
60.27 ± 11.49 years. The incidence of chronic HCV infection 
and HBV in our study were 38.3% and 3.9% respectively. At 
diagnosis, the median PLR was 2.5 (range 0.07–42), platelets 
138.5 k/µL (range 5–459 k/µL), and the median PDW was 18.5 
(range 15.6–24.9). Basic data are illustrated in table I.
123
Low PLR (<2.5) was more frequently observed in male 
patients (p = 0.06) with stage C (p < 0.001), with 17p deletion 
(p  =  0.017), and CD38 expression (p = 0.08) and intention 
to treat (p < 0.001), but not with HCV seropositive patients 
(p = 0.22) and ZAP-70 positivity (p = 0.28) (table II). 
High PDW (≥18.5 fl) was more frequently associated with 
intention to treat population (p = 0.038), and CD38 expression 
(p = 0.068), but not with 17p deletion (p = 0.25) and seropo-
sitive HCV patients (p = 0.43) (table III).
The median time to initiate treatment in CLL patients was 
2.05 years. It was found that the majority of intention to treat 
population was associated with low PLR (p < 0.001), high 
PDW (p = 0.038), seropositive HCV (p 0.027) and seropostive 
HBV (p = 0.2).
The median overall survival of the studied group was 
5.58 years. CLL patients with stage A, hepatitis C seronegative 
patients, low PDW, high PLR were associated with superior 
overall survival with significant value (p = 0.001, 0.017, 0.043, 
and 0.002 respectively figure 1a, b, c). Multivariate analysis sho-
wed that stage A and low PDW were independent factors for 
OS (p = 0.014 and 0.04 respectively), while high PLR (p = 0.05), 
and seronegative C (p = 0.1) lost their significance.
Discussion 
CLL is considered a heterogeneous disorder associated with 
different clinical courses which were predicted by staging sys-
tems of Binet and Rai. However, these systems do not consider 
other CLL biological features which can affect the course of 
the disease [7, 8]. 
Hitherto, new molecular advances have resulted in the use 
of expensive and complicated prognostic markers like cytogene-
tic aberrations (17p deletions, 11q deletions and trisomy 12), β2 
micro-globulin, IGHV mutational status, expression of CD38 and 
ZAP-70 and gene mutations like NOTCH1, MYD88 and SF3B1 [9]. 
Unfortunately, most of these biomarkers were not taken 
in all of our cases because of either the cost and or unava-
ilability. Another limitation to this study would be immune 
thrombocytopenia. However, to the best of our knowledge, 
Table I. Basic data of studied cases 
Character Value Percentage 
Male/female 101/79 56.1%/43.9%
HCV positive  69 38.3%
HBV positive 7 3.9%
B symptoms – present 107 59%
Median Range 
WBC (k/uL) 61.85 8–960
ALC (k/uL) 52.5   6–900
HB (g/dl) 11 4.3–16.2
Platelet (k/uL) 138.5 5–459 
PLR 2.5 0.07–42
PDW 18.5 15.6–24.9
Stage Number %
A 3 1.7%
B 94 52.2%
C 83 46.1%
Prognostic markers
17p deletion positive (n = 35) 5 14.28%
CD38 positive (n = 93) 33 35.48%
ZAP-70 positive (n = 30) 18 60%
PLR Value No (%)
Low PLR <2.5 86 (47.8%)
High PLR ≥2.5 94 (52.2%)
PDW No (%)
Low PDW <18.5 fl 82 (45.6%)
High PDW ≥18.5 fl 98 (54.4%)
Intention to treat – population                     138                         76.7%
Treatment protocol No %
Wait and watch 19 10.6%
Purine based 53 29.4%
Alkylators based 108 60%
Status (alive/dead) 115/65 63.9%/36.1%
Table II. Comparison between low PLR and high PLR group in CLL patients
Low PLR (<2.5) High PLR (≥2.5) Test of significance p
Male  59 (62.76%) 42 (48.84%) 3.53 0.06
Age >65 34 (36.17%) 29 (33.72%) 0.12 0.7
HCV positive 40 (42.55%) 29 (33.72%) 1.48 0.22
HBV positive 4 (4.26%) 3 (3.48%) 0.07 0.54
Stage A 1 (1.06%) 2 (2.33%)
19.26 <0.001B 35 (37.23%) 59 (68.6%)
C 58 (58%) 25 (29.06%)
Intention to treat population 83 (88.29%) 55 (63.95%) 14.87 <0.001
CD38 positive 21 (43.75%) 12 (26.66%) 2.96 0.08
ZAP-70 positive 10 (71.4%) 8 (50%) 1.4 0.28
del (17p) 5 (23.8%) 0 (0%) 5.65 0.017
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extreme thrombocytopenia and their work up did not reveal 
an immune phenomenon.
Recently, correlation between cancer and inflammation is an 
important new area of research. The antitumour activity of inflam-
mation and the associated immune activation, induce tumour 
growth and progression. Inflammation is an independent predic-
tor for response to therapy, event-free survival and overall survival 
(OS) in diffuse large B-cell lymphoma (DLBCL) patients [10].
Molica et al. have reported that in newly diagnosed CLL 
patients, the doubling time of absolute lymphocytic count 
was an independent predictor of outcomes in those patients 
[11]. Although platelet count prognostic value in CLL is not 
well identified, thrombocytopenia is considered a treatment 
indication [6]. Also, some studies have found that thrombo-
cytopenia results in a compensatory thrombopoietin release 
which might correlate to some prognostic markers like ZAP-70 
and CD38 [12, 13]. So, we used the PLR as it is an easily ap-
plicable clinical method that could detect the patients with 
a poor prognosis early.
Table III. Comparison between low PDW and high PDW group in CLL patients
Low PDW (<18.5 fl) High PDW (≥18.5 fl) Test of significance p
Male  42 (51.2%) 59 (60.2%) 1.46 0.23
Age >65 24 (29.3%) 39 (39.8%) 2.17 0.14
HCV positive 34 (41.5%) 35 (35.7%) 0.62 0.43
HBV positive 4 (4.9%) 3 (3.1%) 0.39 0.53
Stage A 2 (2.4%) 1 (1%)
1.12 0.56B 45 (54.9%) 49 (50%)
C 35 (42.7%) 48 (49%)
Intention to treat population 57 (69.5%) 81 (82.7%) 4.31 0.038
CD38 positive 9 (24.3%) 24 (42.9%) 3.34 0.068
ZAP-70 positive 7 (43.8%) 11 (78.6%) 3.77 0.052
del (17p) 2 (28.6%) 3 (10.7%) 1.45 0.227
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Figure 1b. Effect of PDW on overall survival of studied population 
Survival Functions
OS
0 2.0 4.0 6.0 8.0 10.0 12.0
0.0
0.2
0.4
0.6
0.8
1.0
Cu
m
 S
ur
vi
va
l
HCV
low PLRhigh PLR
0-censored 1-censored
p = 0.002
Figure 1c. Effect of PLR on overall survival of studied population
patients with auto-immune hematologic manifestations were 
not included in this analysis. Only two patients presented 
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Figure 1a. Effect of HCV infection on overall survival of studied 
population 
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Cytopenia in patients with CLL can have multiple causes 
including progressive bone marrow (BM) infiltration by ab-
normal lymphocytes, autoimmune disease, therapy-related, 
non-CLL related disorders, or a combination of these mecha-
nisms [14]. The biological rationale in calculating PLR is that 
lymphocytosis and thrombocytopenia often occured in the 
advanced stages of CLL [6].
Our data demonstrated that Low PLR (<2.5) group was 
significantly associated with poor prognostic markers; stage 
C (p < 0.001), with 17p deletion (p = 0.017), and intention to 
treat (p < 0.001). They had significantly shorter OS compared 
to high PLR (p = 0.002) in a univariate analysis, while they lost 
their significance in multivariate analysis (p = 0.05). In solid 
tumours, a positive relationship between high PLR with worse 
prognosis for colorectal, gastroesophageal, hepatocellular, 
pancreatic, and ovarian cancers was identified [15]. 
Meanwhile, Kang et al. demonstrated that PLR had si-
gnificant association with a poor prognosis in patients with 
non-Hodgkin’s lymphoma, treated by R-CHOP [16]. Wang et 
al. reported that high PLR was associated with shorter OS and 
PFS in patients with DLBCL [10], also Seo et al. found that PLR 
showed independent significance in patients with advanced 
stage marginal zone lymphoma treated with rituximab, vin-
cristine, cyclophosphamide, and prednisone protocol [17]. 
Retrospective analysis of 283 myeloma patients showed that 
inverse PLR had predictive value for OS and PFS [18]. 
Despite recent interest in the clinical implications of acti-
vated platelets in the setting of cancer, the scope of available 
data is still limited by the type of malignancy, sample sizes, 
selected population and clinical outcomes studied. PDW is 
a measure of platelet heterogeneity caused by heterogeneous 
demarcation of megakaryocytes. Several cytokines such as IL6, 
granulocytes colony stimulating factor (G-CSF) and macropha-
ge colony stimulating factor (M-CSF) have dual functions inc-
luding regulating megakaryopoiesis and tumour progression 
[19]. Another possible mechanism is that activated platelets 
create a procoagulant micro-environment that protect the 
tumour cells from the host immune system [20].
Increased PDW was found in gastric cancer and lung can-
cer [21, 22], and has been demonstrated to have a poor pro-
gnostic impact in melanoma, thyroid cancer, colorectal cancer, 
and laryngeal cancer. Also, studies, found that an increased 
PDW was associated with advanced TNM stages and shortened 
OS in patients with nasopharyngeal cancer. In contrast, other 
studies showed that decreased PDW was found in thyroid and 
breast cancer [23, 24], and is an unfavourable predictive factor 
for non-small cell lung cancer patient survival [25].
To the best of our knowledge, our study is the first to 
demonstrate the effect of high PDW in CLL patients and it 
revealed that High PDW (≥18.5 fl) was more frequently asso-
ciated with intention to treat population (p = 0.038), and CD38 
expression (p = 0.068), but not with 17p deletion (p = 0.25) 
and seropositive HCV patients (p = 0.4).
Conclusions 
The low PLR and high PDW are associated with poor prognostic 
markers in CLL patients. CLL staging and PDW are independent 
predictors of survival. Unfortunately, the other prognostic mar-
kers as 17p deletion, CD38 and ZAP-70 were not performed 
for all our patients. We recommend further prospective studies 
to evaluate these simple applicable and cheap biomarkers in 
larger numbers of patients. 
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